The Brigham Expands Use of ECMO During COVID-19

extracorporeal membrane oxygenation (ECMO) machine

In March of 2020, Brigham and Women’s Hospital purchased four additional extracorporeal membrane oxygenation (ECMO) machines to prepare for a possible surge of COVID-19. It wasn’t yet clear if ECMO could support critically ill COVID-19 patients, but early reports from China had shown promise.

Read More

Brigham Takes on Leadership Role in COVID-19 Vaccine Trials

Person gettting vaccine in arm

A late-stage clinical trial is now underway at Brigham and Women’s Hospital to test a vaccine candidate for preventing COVID-19. The Brigham is the only hospital in New England to serve as a clinical research site in the phase 3 COVE study. The study is designed to evaluate the effectiveness and safety of the vaccine, mRNA-1273, and its ability to prevent COVID-19 illness.

Read More

Treating Critically Ill Pregnant Patients with COVID-19

pregnant woman in hospital bed

At Brigham and Women’s Hospital, the Department of Obstetrics and Gynecology and Division of Maternal-Fetal Medicine have a long history of caring for patients with complex health conditions that affect pregnant women, including placenta accreta and heart disease.

Read More

Outpatient Prenatal Care During COVID-19

Pregnant woman having virtual visit with doctor

The COVID-19 pandemic has uniquely affected outpatient prenatal care, which depends on frequent assessment of a pregnant mother and her fetus. At the start of the pandemic, the outpatient prenatal care program at Brigham and Women’s Hospital increased the use of virtual visits, allowing patients to regularly meet with their providers safely.

Read More

First Nationwide Study of Critically Ill COVID-19 Patients

anesthetist with patient

Investigators at Brigham and Women’s Hospital led the first study that offers national data on the factors that may increase the risk of complications or death in critically ill COVID-19 patients. David E. Leaf, MD, MMSc and Shruti Gupta, MD, MPH, physicians in the Brigham’s Division of Renal Medicine, led a team of more than 300 investigators from over 65 hospitals across the U.S. to examine the demographics, comorbidities, organ dysfunction, treatment and outcomes of patients with COVID-19 admitted to intensive care units (ICUs). Read More

Universal Masking Prevents SARS-CoV-2 Transmission

Doctors in masks

In March of 2020, Mass General Brigham (MGB) implemented a universal masking policy that required all staff in the health care system to wear a surgical mask while in the hospital. MGB is comprised of 78,000 employees across 12 Massachusetts-based hospitals, including Brigham and Women’s Hospital and Massachusetts General Hospital (MGH).

Read More

iMASC: A New Reusable, Scalable and Comfortable Face Mask

Mannequin wearing face mask and gogglesThe Injection Molded Autoclavable, Scalable, Comfortable (iMASC) system developed by bioengineers and clinicians at Brigham and Women’s Hospital.

At Brigham and Women’s Hospital, the biomedical research lab of Giovanni Traverso, MB, BChir, PhD recently developed a new reusable, scalable alternative to N95 masks, which have been in short supply within healthcare settings during the COVID-19 pandemic.

Read More

Deceased COVID-19 Patients Show Hypoxic Injury in the Brain

Human brain
Coronal view of one of the 18 human brains in a study led by Isaac H. Solomon, MD, PhD, a pathologist at Brigham and Women’s Hospital.

While COVID-19 primarily affects the lungs of those infected, many patients have reported a wide range of unusual neurological symptoms. These include headaches, altered mental status, strokes, seizures and loss of smell. Many researchers have hoped that autopsies could shed light on the unknowns of COVID-19, caused by the novel coronavirus SARS-CoV-2.

Read More

Case Series: Teriflunomide Therapy in COVID Patients with MS

Brain scanFrom 7T MRI performed at Brigham and Women’s Hospital in Study Patient 1. This is a T2* gradient-echo sequence (0.8 mm isotropic voxels) showing a typical MS lesion (arrow) as oval, and bright, containing a central (dark) vessel.

During the COVID-19 pandemic, patients with multiple sclerosis (MS) and their clinicians have had questions and concerns about whether immunotherapies for MS could influence risk for infection or lead to an unfavorable outcome.

Read More

Remdesivir at Forefront of Battle Against COVID-19

Pill bottles of remdisivir

Remdesivir has emerged as a promising therapeutic candidate for the treatment of COVID-19 due to its ability to inhibit pathogenic animal and human coronaviruses, including severe acute respiratory syndrome 2 (SARS-CoV-2) and Middle East Respiratory Syndrome coronavirus (SARS-CoV-1).

Read More